BCL2 and diffuse large B-cell lymphoma: For instance, ibrutinib could be beneficial in MCD and BN2 DLBCL, which are characterized by predominant B cell receptor-dependent NF-kB activation, while BH3 mimetics might be particularly beneficial in the EZB subtype, which shows frequent BCL2 translocations [14,16,17].